Latest news about Amanta Healthcare
Amanta Healthcare
132.26
+9.93(+8.12%)
Company Performance:
View Company Insights1D+8.12%
1M+0.86%
6M+27.85%
1Y-6.69%
5Y-6.69%
More news about Amanta Healthcare
23Apr 26
Amanta Healthcare Clarifies Promoter Share Acquisition with Credit of Remaining 15,500 Shares
Amanta Healthcare Limited has clarified that the remaining 15,500 equity shares purchased by promoter Shri Bhavesh Patel on March 30, 2026, were credited to his demat account on April 17, 2026. This completes the acquisition of 28,800 shares, increasing his shareholding from 63,11,044 shares (16.25%) to 63,26,544 shares (16.29%). The company has requested stock exchanges to update their records with this revised information.
16Apr 26
Amanta Healthcare Limited Announces Resignation of Senior Management Personnel
Amanta Healthcare Limited announced the resignation of Shri Vimal Shrimali, AVP – HR & ADMIN, effective April 16, 2026, due to personal reasons. The company has notified stock exchanges BSE and NSE about this senior management change in compliance with SEBI regulations. Shrimali expressed willingness to assist with transition processes for smooth handover of responsibilities.
09Apr 26
Amanta Healthcare Completes Analyst Meeting and Site Visit at Kheda Facility
Amanta Healthcare Limited has successfully completed its scheduled analyst and institutional investor meeting on April 7, 2026, at its Kheda, Gujarat facility. The meeting included group discussions and site visits, with company officials sharing only publicly available information while ensuring no Unpublished Price Sensitive Information was disclosed, maintaining full compliance with SEBI regulations.
08Apr 26
Amanta Healthcare Limited Files SEBI Compliance Certificate for Quarter Ended March 31, 2026
Amanta Healthcare Limited submitted its quarterly compliance certificate to BSE and NSE for the quarter ended March 31, 2026, under SEBI regulations. The certificate, provided by registrar MUFG Intime India Private Limited, confirms proper handling of dematerialized securities and adherence to prescribed timelines. Company Secretary Nikhita Dinodia signed the April 8, 2026 submission, ensuring regulatory compliance with stock exchange requirements.
02Apr 26
Amanta Healthcare Limited Files Annual SEBI SAST Disclosures for FY 2025-26
Amanta Healthcare Limited filed annual disclosures under SEBI SAST Regulations for FY 2025-26 on April 2, 2026, with both BSE and NSE. The promoter group, led by Chairman & Managing Director Bhavesh G. Patel, declared no encumbrance on company shares during the financial year. The compliance filing was coordinated by Company Secretary Nikhita Dinodia, ensuring adherence to regulatory requirements under Regulation 31(4) of SEBI SAST Regulations, 2011.
01Apr 26
Amanta Healthcare Promoter Increases Stake Through Open Market Purchase of 28,800 Shares
Amanta Healthcare disclosed that promoter Bhavesh Girishbhai Patel acquired 28,800 equity shares worth ₹28,18,826 through open market purchases on March 27 and March 30, 2026. The transactions increased his shareholding from 62,97,744 shares (16.22%) to 63,26,544 shares (16.29%). The company filed the mandatory disclosure under SEBI Insider Trading Regulations on April 1, 2026, demonstrating regulatory compliance.
28Mar 26
Bandhan Mutual Fund Files SEBI Disclosure After Crossing 5% Stake in Amanta Healthcare
Bandhan Mutual Fund through its Small Cap Fund acquired 21,603 equity shares of Amanta Healthcare on March 25, 2026, increasing its holding from 4.9568% to 5.0124%. The fund filed mandatory SEBI disclosure under Regulation 29(1) of SAST Regulations 2011, with formal notification submitted to BSE on March 27, 2026.
26Mar 26
Amanta Healthcare Reports Insider Purchase of 15,675 Equity Shares by Director's Relative
Amanta Healthcare Limited disclosed that Ms. Dypal Jain, immediate relative to Director Shri Nitin Jain, purchased 15,675 equity shares through open market transactions between March 19-24, 2026, valued at ₹15.01 lakh. The transactions were executed on NSE and BSE exchanges, increasing her total shareholding to 15,676 shares (0.04% of equity capital). The company submitted the required SEBI insider trading disclosure on March 26, 2026.
27Feb 26
Amanta Healthcare Promoter Increases Stake Through Open Market Purchase
Amanta Healthcare Limited disclosed that promoter Bhavesh Girishbhai Patel acquired 48,151 equity shares worth ₹50.20 lakh through open market purchases on February 26-27, 2026. The transaction increased his shareholding from 62,49,593 shares (16.10%) to 62,97,744 shares (16.22%). The disclosure was made under SEBI Insider Trading Regulations with shares purchased through NSE market transactions.
16Feb 26
Amanta Healthcare Hosts Maiden Earnings Call, Outlines ₹150 Crore Revenue Expansion Plan
Amanta Healthcare held its first earnings conference call following Q3FY26 results, with management detailing major expansion plans including doubling SteriPort capacity and SVP line enhancement. The company projects ₹150 crore incremental revenue from these initiatives, targeting overall revenue of ₹400 crore by FY27, while implementing cost optimization through a 10.8 MW solar plant expected to save ₹9 crore annually.
10Feb 26
Amanta Healthcare Limited Announces Changes in Senior Management Personnel
Amanta Healthcare Limited announced changes in its senior management personnel effective February 10, 2026, with Board approval for the inclusion of Shri Urmil Oza as Senior Management Personnel and removal of Shri Shailesh Shah. Urmil Oza, Vice President - Engineering, brings 30 years of experience including 26 years with the company, specializing in production engineering, utility management, and regulatory compliance. The company has notified BSE and NSE about these changes in compliance with SEBI regulations.
02Feb 26
Amanta Healthcare Opens Special Window for Transfer and Dematerialisation of Physical Securities
Amanta Healthcare Limited has opened a special window for transfer and dematerialisation of physical securities from February 05, 2026 to February 04, 2027, following SEBI Circular dated January 30, 2026. The one-year window allows investors to re-lodge transfer deeds for securities sold or purchased prior to April 01, 2019 that were previously rejected due to document deficiencies. Investors can submit complete documentation to MUFG Intime India Private Limited, the company's Registrar and Transfer Agent based in Ahmedabad.
02Jan 26
Amanta Healthcare Corrects Solar Power Plant Capacity to 10.8 MWp in Revised Agreement
Amanta Healthcare Limited issued a correction regarding its solar power plant project with Zodiac Energy Limited, rectifying the capacity from an erroneously reported 10.8 KWp to the correct 10.8 MWp. The company re-executed the agreement on January 02, 2026, maintaining all other terms and conditions while confirming regulatory compliance under SEBI regulations.
14Nov 25
Amanta Healthcare Allocates Rs 3,030 Crore from IPO Proceeds for Expansion
Amanta Healthcare Limited has used Rs 3,030.02 lakhs from its IPO proceeds for the quarter ending September 30, 2025. The funds were primarily used for capital expenditure at its Gujarat facility, including manufacturing equipment and civil construction. The company still has Rs 9,569.98 lakhs available for further planned expansions. Amanta plans to commence a SteriPort Manufacturing Line in January 2026 and an SVP Manufacturing Line in January 2027, both located in Hariyala, Kheda, Gujarat. For Q2 FY2026, the company reported a total income from operations of Rs 7,095.80 lakhs and a net profit after tax of Rs 120.76 lakhs.
12Nov 25
Amanta Healthcare Reports Fund Utilization Deviation and Q2 FY2026 Financial Results
Amanta Healthcare Limited disclosed a deviation in IPO fund utilization due to GST payment changes, adjusting issue expenses and reducing general corporate purpose expenses. The company's Q2 FY2026 results show revenue growth to Rs. 7,088.73 lakhs, but a decrease in net profit to Rs. 120.75 lakhs compared to Q2 FY2025. Half-year performance improved with revenue at Rs. 13,619.44 lakhs and net profit at Rs. 471.47 lakhs. Balance sheet highlights include increased total assets of Rs. 48,831.55 lakhs and improved cash position of Rs. 9,196.41 lakhs as of September 30, 2025.
12Nov 25
Amanta Healthcare Reports Q2 Profit, Completes IPO Listing
Amanta Healthcare Limited reported Q2 FY2026 results with total income of Rs. 7,095.80 lakhs and net profit of Rs. 207.80 lakhs. For H1 FY2026, total income was Rs. 13,850.45 lakhs with net profit of Rs. 185.50 lakhs. The company completed its IPO, issuing 10 million shares at Rs. 126 each, raising Rs. 12,600 lakhs. Listing occurred on September 9, 2025, on BSE and NSE. IPO proceeds are allocated for new manufacturing lines and corporate purposes, with Rs. 3,030.02 lakhs utilized so far. PriceWaterhouseCoopers provided an unmodified review opinion on the financial results.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,780.10
(-0.47%)
6,596.50
(+0.30%)
4,339.90
(-0.65%)
1,398.70
(+1.71%)
1,084.60
(+0.74%)
1,267.50
(+0.33%)
2,249.80
(-0.50%)
2,353.00
(-0.70%)
1,463.60
(+1.61%)
1,427.20
(+2.36%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
